Biotech Values

[jq1234]

The efficacy result is on par with Cabazitaxel because these two were tested in same patient population. The difference is in the control arm, mitoxantrone and prednisone/prednisolone vs prednisone/prednisolone and placebo.

Cabazitaxel primary end point (overall survival) showed that the combination of cabazitaxel and prednisone/prednisolone significantly reduced the risk of death by 28% [HR=0.72 (95% CI: 0.61-0.84); P<0.0001] with an improvement in the median overall survival of 15.1 months vs. 12.7 months in the mitoxantrone and prednisone/prednisolone combination arm.

Abiraterone acetate in combination with prednisone/prednisolone led to a 35% reduction in the risk of death (HR=0.65; 95% CL: 0.54-0.77; P<0.0001) that translated into a median 14.8 month survival compared with 10.9 months for patients who received prednisone/prednisolone and placebo.

Abiraterone acetate has advantage in AE profile relative to Cavazitaxel.